24.81

6.87% -1.83

Jyong Biotech Ltd (MENS)

Overview News Price History Discussions Forecast

Jyong Biotech Ltd stock is traded at $24.81, with a volume of 221.43K. It is down -6.87% in the last 24 hours and down -32.40% over the past month. Jyong Biotech Ltd is a science-driven biotechnology company based in Taiwan and is committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia (primarily Taiwan and mainland China). It has been dedicated to the research and development of new drugs with high safety and efficacy. It has been developing a series of drug candidates, including one core drug candidate at NDA stage, one clinical-stage key drug candidate and other preclinical-stage drug candidates.

Previous Close:

$26.64

Open:

$26.35

24h Volume:

221.43K

Relative Volume:

0.65

Market Cap:

$1.89B

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

-15.03%

1M Performance:

-32.40%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1-Day Range:

$22.51

$28.10

1-Week Range:

$22.51

$29.30

52-Week Range:

$9.95

$67.00

Jyong Biotech Ltd Stock (MENS) Company Profile

Name

Jyong Biotech Ltd

Sector

Healthcare (1123)

Industry

Biotechnology (627)

Phone

Address

Employee

Twitter

Next Earnings Date

Latest SEC Filings

MENS's Discussions on Twitter

Compare MENS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MENS Jyong Biotech Ltd	24.81	2.03B	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	452.04	113.14B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	741.29	78.49B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	877.94	54.76B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	397.55	54.51B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	197.01	41.64B	447.02M	-1.18B	-906.14M	-6.1812

Jyong Biotech Ltd Stock (MENS) Latest News

Dec 10, 2025

Jyong Biotech Shares Becomes Oversold (MENS) - Nasdaq

Dec 10, 2025

Jyong Biotech (NASDAQ:MENS) Trading Down 5.9%Here's Why - MarketBeat

Dec 10, 2025

Dec 08, 2025

Jyong Biotech Ltd.'s (NASDAQ:MENS) Lock-Up Period Will End on December 15th - MarketBeat

Dec 08, 2025

Jyong Biotech Ltd.’s (NASDAQ:MENS) Lock-Up Period Will End on December 15th - Defense World

Dec 08, 2025

Dec 07, 2025

Jyong Biotech (NASDAQ:MENS) Shares Gap Down – Here’s Why - Defense World

Dec 07, 2025

Dec 06, 2025

Taiwan's Jyong Biotech expands regional partnership with MoU signing in Vietnam - BioSpectrum Asia

Dec 06, 2025

Dec 05, 2025

Jyong Biotech (NASDAQ:MENS) Stock Price Down 4.3%Time to Sell? - MarketBeat

Dec 05, 2025

Dec 04, 2025

Jyong Biotech expands regional partnerships, signs MoU with a Vietnam pharmaceutical distributor - marketscreener.com

Dec 04, 2025

Jyong Biotech Expands Regional Partnerships, Signs MoU With A Vietnam Pharmaceutical Distributor - TradingView — Track All Markets

Dec 04, 2025

Jyong Biotech: Speculative BPH And Prostate Cancer Prevention Story (NASDAQ:MENS) - Seeking Alpha

Nov 27, 2025

Nov 26, 2025

Jyong Biotech (NASDAQ:MENS) Stock Price Down 9.6%What's Next? - MarketBeat

Nov 26, 2025

Taiwan's Jyong Biotech announces partnership in Korea to evaluate in‑licensing of plant-derived MCS drugs - BioSpectrum Asia

Nov 26, 2025

Nov 25, 2025

Jyong Biotech signs letter of intent with South Korean pharma company - Investing.com Australia

Nov 25, 2025

Nov 24, 2025

Jyong Biotech to Evaluate Licensing Deal for MCS-2 Drug Candidate in South Korea - marketscreener.com

Nov 24, 2025

Jyong Biotech signs letter of intent with South Korean pharma company By Investing.com - Investing.com South Africa

Nov 24, 2025

Jyong Biotech Ltd. Signs Non‑Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In‑Licensing of Plant-Derived MCS Drugs - The Manila Times

Nov 24, 2025

Jyong Biotech (Nasdaq: MENS) LOI to Evaluate MCS-2 Licensing with Korean Pharma - Stock Titan

Nov 24, 2025

Nov 21, 2025

Jyong Biotech (NASDAQ:MENS) Shares Up 10.9%Should You Buy? - MarketBeat

Nov 21, 2025

Jyong Biotech completes primary endpoint analysis for Phase II trial of MCS-8 - Yahoo Finance

Nov 21, 2025

Exploring Jyong Biotech’s (NasdaqGM:MENS) Valuation Following Recent Share Price Volatility - Yahoo Finance

Nov 21, 2025

Nov 20, 2025

Jyong Biotech reports positive results for prostate cancer drug in phase II trial - Investing.com Nigeria

Nov 20, 2025

Jyong Biotech stock soars after positive Phase II prostate cancer drug results - Investing.com Nigeria

Nov 20, 2025

Jyong Biotech stock soars after positive Phase II prostate cancer drug results By Investing.com - Investing.com South Africa

Nov 20, 2025

Jyong Biotech Says Phase 2 Trial of MCS-8 in Prostate Cancer Meets Efficacy Endpoints - marketscreener.com

Nov 20, 2025

Jyong Biotech announces completion of primary endpoint statistical analysis for phase II clinical trial of MCS-8 with positive outcomes - MarketScreener

Nov 20, 2025

Jyong Biotech Announces Completion of Primary Endpoint Statistical Analysis for Phase II Clinical Trial of MCS-8 With Positive Outcomes - The Manila Times

Nov 20, 2025

Jyong Biotech Announces Completion of Primary Endpoint - GlobeNewswire

Nov 20, 2025

Nov 19, 2025

Jyong Biotech (NASDAQ:MENS) Shares Gap DownTime to Sell? - MarketBeat

Nov 19, 2025